MEDICATIONS DEVELOPMENT FOR STIMULANT DEPENDENCE (MDS)

RELEASE DATE:  March 26, 2002

NOTICE:  NOT-DA-02-023

RFP AVAILABLE:  N01DA-2-8824

National Institute on Drug Abuse (NIDA)
 (www.nida.nih.gov)

The National Institute on Drug Abuse (NIDA) is soliciting proposals 
from qualified organizations/investigational sites having the 
capability to conduct Phase I, II or III clinical trials of potential 
treatment drugs, both investigational and marketed, for the treatment 
of drug addiction. Specifically, NIDA will clinically investigate 
treatment drugs for stimulants and possibly opiates under the current 
Food and Drug Administration regulations and Good Clinical Practice 
guidelines. The offeror will provide all the necessary services to 
conduct clinical trials. Experience in conducting clinical pharmacology 
for Phase I, II  or III clinical trials in addiction medicine is 
required. Due to the nature of the study compounds, it is mandatory 
that offerors possess a Drug Enforcement Administration (DEA) Research 
Registration for Schedules II to V in order to handle substances under 
the Controlled Substances Act of 1970.  NIDA anticipates multiple 
awards of up to twelve, five-year, task order type contracts as a 
result of this solicitation. NIDA anticipates availability of RFP No. 
N01DA-2-8824 electronically on or about April 10. The RFP will be 
accessible through the FedBizOpps and/or the NIDA website (URL: 
http://www.nida.nih.gov/RFP/RFPList.html). Responses to the RFP are 
due approximately 60 calendar days thereafter.  Please note that NIDA 
uses a streamlined RFP format which includes only the Work Statement, 
Deliverables and Reporting Requirements, Special Requirements and 
Mandatory Qualifications, Technical Evaluation Criteria, and other 
necessary Proposal Preparation Instructions.  All information required 
for the submission of a proposal is contained in or accessible through 
the streamlined RFP package.  Any responsible offeror may submit a 
proposal which will be considered by the Government.  This 
advertisement does not commit the Government to award a contract.  

Point of Contact:

Kenneth E. Goodling, Contracting Officer
National Institute on Drug Abuse, NIH
Contracts Management Branch, OPRM
6001 Executive Blvd., Room 3105, MSC 9543
Bethesda, Maryland  20892-9543
E-mail: kg25d@nih.gov
Telephone: (301) 443-6677
Fax:  (301) 443-7595

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

			Department of Health and Human Services (HHS)
NIH... Turning Discovery Into Health®